LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Затворен

СекторЗдравеопазване

46.75 2.25

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

45.73

Максимум

46.79

Ключови измерители
By Trading Economics
Приходи	2.4B 2.5B
Продажби	-1.1B 11B
P/E Средно за сектора	17.384 56.602
EPS	1.8
Дивидентна доходност	5.15
Марж на печалбата	21.98
Служители	34,100
EBITDA	1.9B 4.5B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+22.79% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	5.15% 2.45%
Следващи печалби	31.07.2025 г.
Следваща дата на дивидент	31.07.2025 г.
Следваща дата на екс-дивидент	4.07.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-17B 95B
Предишно отваряне	44.5
Предишно затваряне	46.75

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

N/A / 50.57 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 11:32 ч. UTC

Печалби

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

13.05.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 17:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12.05.2025 г., 12:07 ч. UTC

Пазарно говорене

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7.05.2025 г., 20:09 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio 1Q Rev $22.9M >TSVT

7.05.2025 г., 20:08 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio 1Q EPS 1c >TSVT

7.05.2025 г., 20:08 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

7.05.2025 г., 20:07 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

29.04.2025 г., 19:47 ч. UTC

Печалби

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29.04.2025 г., 15:22 ч. UTC

Печалби

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29.04.2025 г., 11:46 ч. UTC

Печалби

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29.04.2025 г., 11:42 ч. UTC

Печалби

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29.04.2025 г., 11:12 ч. UTC

Печалби

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

28.04.2025 г., 21:15 ч. UTC

Печалби

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 14:15 ч. UTC

Топ новини

Печалби

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 12:37 ч. UTC

Пазарно говорене

Печалби

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24.04.2025 г., 11:17 ч. UTC

Печалби

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24.04.2025 г., 11:13 ч. UTC

Топ новини

Печалби

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24.04.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

22.79% нагоре

12-месечна прогноза

Среден 56.25 USD 22.79%

Висок 68 USD

Нисък 36 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 50.57Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.